Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years P. Vermersch,M. Baker,A. D. Bass,R. Berkovich, G. Comi,S. Eichau,D. Graves,S. F. Hunter, C. Ionete,V. Limmroth,S. G. Meuth,R. T. Naismith,B. Sharrack, A. Subei,N. Daizadeh,Z. Choudhry,B. Van WijmeerschEUROPEAN JOURNAL OF NEUROLOGY（2019）引用 0|浏览21暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
